191 results about "Obesity" patented technology

Provided herein, in part, is a method of treating or preventing obesity or an obesity-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of an Activin receptor Type II.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The present invention relates to a compound, of the formula:Wherein variables are as defined in the specification and pharmaceutical composition comprising thereof, more specifically compound of the present invention is thiophenyl and pyrrolyl azepine compound; The compound is serotonin receptor (5-HT2c) ligand, useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).

The present invention relates to a benzene-containing polycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in general formula (I-1), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of a drug for treating diabetes, obesity, NASH, renal diseases and diseases associated therewith, wherein each substituent in general formula (I-1) is the same as that defined in the specification.

In the present invention it has been found a pharmaceutical formulation comprising a GLP-1 peptide agonist; a C6-C9 fatty acid or a salt thereof or a combination of a C6- C9 fatty acid or a salt thereof and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid as the sole permeability enhancers can be used to increase the bioavailability of the peptide in the formulation. The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and the C6-C9 fatty acid each act as permeability enhancers, and improve the bioavailability of the peptide. The pharmaceutical formulation can be used in the treatment of diabetes mellitus and obesity.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

A method for determining the indication for the prevention of persistent AR in the form of problem-based learning in primary school children, consisting of determining the body mass index (BMI, kg / m 2 ) within the range of +1 SDS or more, taking into account the age and sex of the child and IL 1β using the enzyme immunoassay method; with IL 1β equal to or more than 0.029 pg / ml, a child with overweight / obesity is classified as being at high risk for the development of persistent AR, requiring prevention in the form of problem-based learning.

The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy.Preferred compounds are, for example, 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as C-1, C-2, C-3, C-4 and other compounds. [Formula 1] TIFF2024514826000258.tif26170 [chemical 2] TIFF2024514826000259.tif58170

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, Y1, Y2, Y3, Z1, Z2 and m are as defined herein.

This invention provides RNAi agents, such as dsRNA agents, that target the G protein-coupled receptor 75 (GPR75) gene. It also provides methods for using such RNAi agents to inhibit the expression of the GPR75 gene in a subject, and methods for treating or preventing GPR75-related diseases such as weight disorders, e.g., obesity. [Solution] A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of the GPR75 gene in cells is provided, comprising a sense strand and an antisense strand that form a double-stranded region, wherein the antisense strand comprises a region complementary to a portion of the mRNA encoding the GPR75 gene, each strand is independently 14 to 30 nucleotides long, and the sense strand or antisense strand is conjugated to one or more lipophilic portions.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

The present invention relates to a crystalline form I represented by Formula 1, which may be characterized by XRD patterns, DSC profiles, and / or TGA profiles, a method for preparing the same, and a pharmaceutical composition comprising the same, useful for the treatment of prevention of obesity, diabetes, inflammation, or erectile dysfunction. (see formula 1) wherein R1 is C2-C5 alkyl.

To provide arginine depleting proteins with improved pharmacokinetics.SOLUTION: The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities.SELECTED DRAWING: None

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

The present invention relates to GLP-1 receptor agonists compounds of Formula I:and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, n, p, A, X, Y and B are as defined herein. The present invention also relates to compositions which comprise a GLP-1 receptor agonist compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating obesity or non-insulin-dependent diabetes mellitus (Type 2 diabetes) comprising administering to a patient a therapeutically effective amount of a compound of the invention.

The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

Examples relate to a method comprising using a non-target tissue model to virtually purify an experimental electrical impedance signal with respect to target tissue. A method comprisingobtain a purifying impedance transfer function based on an electrical impedance model with one or more non-target tissue components and without a target tissue component; andpurifying an experimental electrical impedance signal using the purifying impedance transfer function to obtain a virtually purified signal for the target tissue component. A method comprising: in dependence upon age and / or a measure of obesity, access an impedance transfer function dependent upon non-tumor tissue; modify an experimental electrical impedance signal using the obtained impedance transfer function to obtain a signal less dependent upon non-tumor tissue and more dependent upon tumor tissue impedance.

This paper provides a system and method for selecting weight-loss medications using machine learning models to address obesity. [Solution] System 100 receives physiological measurements from the user and applies the measurements to a machine learning model. The machine learning model can be trained using multiple examples, each example including sample physiological measurements from a sample user and a corresponding sample weight-loss drug administered to the sample user. The system also generates metrics indicating expected outcomes associated with the user's weight-loss drug based on the application of one or more physiological measurements to the machine learning model, and sends a message indicating the expected outcomes associated with the weight-loss drug to the user's associated user device. [Effects] It can improve the effectiveness of weight-loss drugs when dealing with obesity.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.